Lung Cancer

14 protocols meet the specified criteria.

  • A081801

    Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO

  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

  • A211901

    Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

  • EAY191-A3

    A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancer

  • EAY191-N5

    A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial

  • HLX10-005-SCLC301-E

    A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Lung Cancer (ES-SCLC)

  • LUNGMAP

    A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

  • NRG-LU007

    Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

  • NRG-LU008

    Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

  • PRESERVE-003

    Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors

  • S1800E

    LUNGMAP: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Non-Matched Sub-Study)

  • S1827

    MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

  • S1900J

    A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNGMAP Sub-Study)